New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Diagnostic imaging will become an increasingly vital process in healthcare
The company has operationalized diagnostics center at Ferozepur, Gurdaspur, Nawanshahr, and Kapurthala in Punjab.
The lab is also the first private lab in West India to have built its Mycobacteriology, Mycology, and Molecular Biology departments within a separate Bio Safety Level - 3 (BSL3) bio-containment lab
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
The laboratory has the capacity to conduct 30,000+ tests in a month ranging from simple routine tests to semi-specialized and specialized tests
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
The laboratory is equipped to perform high-volume diagnostic testing services
Results reinforce commitment to next-generation oral SERD development programme
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
Subscribe To Our Newsletter & Stay Updated
